Potential First-In-Class Inhibitors of ERAP1, Generating Cancer Antigens As Novel Targets For MHCI-Directed Therapies.
First-on-class Inhibitors of ERAP1 Have The Potential To Be A Transformative Immunotherapy In Oncology.
First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumor growth inhibition.
GRWD5769: A first-in-class Inhibitor of ERAP1, Generating Novel Cancer Antigens to Drive De Novo Anti-Tumor T Cell Responses.
The quickest way to access our posters is to click on the image above and complete the individual poster request form.
If you would like multiple posters, please complete the form below and we will come back to you shortly.
